• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中医药治疗恶性胸腔积液的机制研究进展与应用

Progress in Mechanistic Research and the Use of Traditional Chinese Medicine in Treating Malignant Pleural Effusion.

作者信息

Gong Fengying, Cheng Yunshui, Li Yongchun, Fan Qin, Qu Rongmei, Fan Tingyu, Lv Ying, Dai Jingxing

机构信息

Department of Traditional Chinese Medicine, Nanfang Hospital of Southern Medical University, Guangzhou, 510515, People's Republic of China.

The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, 510405, People's Republic of China.

出版信息

Cancer Manag Res. 2025 Jul 15;17:1377-1388. doi: 10.2147/CMAR.S529467. eCollection 2025.

DOI:10.2147/CMAR.S529467
PMID:40692944
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12277589/
Abstract

Malignant pleural effusion (MPE) is characterized by the accumulation of fluid in the chest cavity, secondary to metastasis from a primary pleural tumor or malignant neoplasms originating from other anatomical sites. MPE is associated with a poor prognosis. Consequently, timely and effective prevention and management of MPE are critical. In Western medicine, the treatment of MPE primarily involves procedures such as surgical puncture for drainage, pleural fixation, chemotherapy, and targeted therapy. In contrast, traditional Chinese medicine (TCM) offers therapeutic modalities including oral decoctions, thoracic perfusion with herbal injections, topical applications of medicinal pastes, and acupoint therapies. The TCM approaches have demonstrated satisfactory clinical outcomes. Advances in the study of TCM for managing MPE in lung tumors are expected to yield a wealth of therapeutic strategies, facilitating the development of more optimized clinical treatments.

摘要

恶性胸腔积液(MPE)的特征是胸腔内液体蓄积,继发于原发性胸膜肿瘤的转移或源自其他解剖部位的恶性肿瘤。MPE预后较差。因此,及时有效地预防和处理MPE至关重要。在西医中,MPE的治疗主要包括手术穿刺引流、胸膜固定、化疗和靶向治疗等操作。相比之下,中医提供的治疗方式包括口服汤剂、中药注射剂胸腔灌注、药膏外敷和穴位疗法。中医方法已显示出令人满意的临床效果。预计中医在肺癌MPE管理方面的研究进展将产生丰富的治疗策略,推动更优化的临床治疗的发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0463/12277589/4f8364b42739/CMAR-17-1377-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0463/12277589/4f8364b42739/CMAR-17-1377-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0463/12277589/4f8364b42739/CMAR-17-1377-g0001.jpg

相似文献

1
Progress in Mechanistic Research and the Use of Traditional Chinese Medicine in Treating Malignant Pleural Effusion.中医药治疗恶性胸腔积液的机制研究进展与应用
Cancer Manag Res. 2025 Jul 15;17:1377-1388. doi: 10.2147/CMAR.S529467. eCollection 2025.
2
Interventions for the management of malignant pleural effusions: a network meta-analysis.恶性胸腔积液管理的干预措施:一项网状Meta分析
Cochrane Database Syst Rev. 2020 Apr 21;4(4):CD010529. doi: 10.1002/14651858.CD010529.pub3.
3
Interventions for the management of malignant pleural effusions: a network meta-analysis.恶性胸腔积液管理的干预措施:一项网状荟萃分析。
Cochrane Database Syst Rev. 2016 May 8;2016(5):CD010529. doi: 10.1002/14651858.CD010529.pub2.
4
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
5
Oral traditional Chinese medication for adhesive small bowel obstruction.口服中药治疗粘连性小肠梗阻。
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD008836. doi: 10.1002/14651858.CD008836.pub2.
6
Retrospective prognostic evaluation and single-cell transcriptomic analyses of non-small cell lung carcinoma with malignant pleural effusion.伴有恶性胸腔积液的非小细胞肺癌的回顾性预后评估及单细胞转录组分析
Transl Cancer Res. 2025 Jun 30;14(6):3500-3519. doi: 10.21037/tcr-2024-2581. Epub 2025 Jun 25.
7
Pleurodesis for malignant pleural effusions.恶性胸腔积液的胸膜固定术
Cochrane Database Syst Rev. 2004(1):CD002916. doi: 10.1002/14651858.CD002916.pub2.
8
Evaluation of a Digital Health Model of Care for the Management of Adults With Symptomatic Malignant Pleural Effusion.用于有症状恶性胸腔积液成人管理的数字健康照护模式评估
Respirol Case Rep. 2025 Jun 18;13(6):e70194. doi: 10.1002/rcr2.70194. eCollection 2025 Jun.
9
Medical Thoracoscopy in Malignant Pleural Effusion.恶性胸腔积液的内科胸腔镜检查
Cureus. 2025 Jun 10;17(6):e85707. doi: 10.7759/cureus.85707. eCollection 2025 Jun.
10
Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer: A systematic literature review and pooled analysis.胸腔内热化疗治疗乳腺癌和卵巢癌所致恶性胸腔积液:系统文献回顾和汇总分析。
Thorac Cancer. 2022 Apr;13(7):883-888. doi: 10.1111/1759-7714.14361. Epub 2022 Feb 22.

本文引用的文献

1
A tellurium-based small compound ameliorates tumor metastasis by downregulating heparanase expression.一种碲基小分子化合物通过下调乙酰肝素酶表达改善肿瘤转移。
J Cancer. 2024 Aug 13;15(16):5308-5317. doi: 10.7150/jca.96001. eCollection 2024.
2
Malignant Pleural Effusion: A Multidisciplinary Approach.恶性胸腔积液:多学科治疗方法
Open Respir Arch. 2024 Jun 19;6(4):100349. doi: 10.1016/j.opresp.2024.100349. eCollection 2024 Oct-Dec.
3
Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer.
单细胞转录组学揭示了晚期非小细胞肺癌患者恶性胸腔积液复发的 CLDN4+转移性癌细胞。
Clin Transl Med. 2024 Apr;14(4):e1649. doi: 10.1002/ctm2.1649.
4
Immune modulation in malignant pleural effusion: from microenvironment to therapeutic implications.恶性胸腔积液中的免疫调节:从微环境到治疗意义
Cancer Cell Int. 2024 Mar 12;24(1):105. doi: 10.1186/s12935-024-03211-w.
5
Application of Aquaporins as Markers in Forensic Pathology: A Systematic Review of the Literature.水通道蛋白作为法医病理学标志物的应用:文献系统综述
Int J Mol Sci. 2024 Feb 25;25(5):2664. doi: 10.3390/ijms25052664.
6
A New Synthesized Dicarboxylated Oxy-Heparin Efficiently Attenuates Tumor Growth and Metastasis.一种新合成的二羧酸化氧肝素有效抑制肿瘤生长和转移。
Cells. 2024 Jan 23;13(3):211. doi: 10.3390/cells13030211.
7
Diagnosis, treatment, and prognosis of stage IB non-small cell lung cancer with visceral pleural invasion.伴有脏层胸膜侵犯的ⅠB期非小细胞肺癌的诊断、治疗及预后
Front Oncol. 2024 Jan 15;13:1310471. doi: 10.3389/fonc.2023.1310471. eCollection 2023.
8
Malignant pleural effusion: current understanding and therapeutic approach.恶性胸腔积液:当前的认识和治疗方法。
Respir Res. 2024 Jan 19;25(1):47. doi: 10.1186/s12931-024-02684-7.
9
NRP1 interacts with endoglin and VEGFR2 to modulate VEGF signaling and endothelial cell sprouting.NRP1 与内皮糖蛋白和 VEGFR2 相互作用,调节 VEGF 信号和血管内皮细胞出芽。
Commun Biol. 2024 Jan 19;7(1):112. doi: 10.1038/s42003-024-05798-2.
10
Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis.靶向VEGF/VEGFR轴的抗血管生成抑制剂的最新进展
Front Pharmacol. 2024 Jan 4;14:1307860. doi: 10.3389/fphar.2023.1307860. eCollection 2023.